Omeros Corporation Company Profile (NASDAQ:OMER)

About Omeros Corporation (NASDAQ:OMER)

Omeros Corporation logoOmeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:OMER
  • CUSIP: 68214310
  • Web: www.omeros.com
Capitalization:
  • Market Cap: $849.02 million
  • Outstanding Shares: 44,803,000
Average Prices:
  • 50 Day Moving Avg: $20.81
  • 200 Day Moving Avg: $19.50
  • 52 Week Range: $7.80 - $27.09
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.07
  • P/E Growth: -0.17
Sales & Book Value:
  • Annual Revenue: $53.6 million
  • Price / Sales: 15.84
  • Book Value: ($1.23) per share
  • Price / Book: -15.41
Profitability:
  • EBITDA: ($48,150,000.00)
  • Net Margins: -117.61%
  • Return on Assets: -62.51%
Debt:
  • Debt-to-Equity Ratio: -1.49%
  • Current Ratio: 2.15%
  • Quick Ratio: 2.11%
Misc:
  • Average Volume: 685,995 shs.
  • Beta: 3.57
  • Short Ratio: 11.73
 

Frequently Asked Questions for Omeros Corporation (NASDAQ:OMER)

What is Omeros Corporation's stock symbol?

Omeros Corporation trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros Corporation's earnings last quarter?

Omeros Corporation (NASDAQ:OMER) issued its earnings results on Tuesday, August, 8th. The company reported ($0.23) EPS for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.12. The business earned $17.15 million during the quarter, compared to analyst estimates of $14.63 million. Omeros Corporation's quarterly revenue was up 71.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.32) earnings per share. View Omeros Corporation's Earnings History.

When will Omeros Corporation make its next earnings announcement?

Omeros Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Omeros Corporation.

Where is Omeros Corporation's stock going? Where will Omeros Corporation's stock price be in 2017?

7 brokerages have issued 12-month price targets for Omeros Corporation's shares. Their predictions range from $19.00 to $75.00. On average, they anticipate Omeros Corporation's share price to reach $37.40 in the next year. View Analyst Ratings for Omeros Corporation.

What are analysts saying about Omeros Corporation stock?

Here are some recent quotes from research analysts about Omeros Corporation stock:

  • 1. Maxim Group analysts commented, "Omeros announced successful treatment with OMS721 of a patient having both stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and graft vs. host disease (GvHD). The data were presented at the European Society for Blood and Marrow Transplantation (EBMT) Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT." (10/20/2017)
  • 2. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (10/19/2017)
  • 3. Cantor Fitzgerald analysts commented, "Omeros announced that it received breakthrough therapy designation for its MASP-2 inhibitor, OMS721, for the treatment of IgA nephropathy (IgAN)." (6/13/2017)
  • 4. Wedbush analysts commented, "The Wedbush View: With an emerging pipeline of rare disease focused products and OMIDRIA sales offsetting the company’s burn, we believe OMER to be an attractive investment for investors with a 2017-2018 horizon." (5/10/2017)
  • 5. Needham & Company LLC analysts commented, "OMER's 4Q16 results, driven by Omidria sales that slightly bested consensus, came slightly ahead of Street expectations. Omidria sales are now annualizing at ~$52MM, which gives us confidence that sales can ramp up to the mid-$60MM range in 2017. Our concern with Omidria rests with the transitional passthrough reimbursement that potentially expires on 1/1/2018. If reimbursement is not extended, Omidria will likely be reimbursed as part of a procedural bundled payment, which would likely impact its current price. On the pipeline front, the OMS721 ph 3 trial for aHUS is now open for enrollment. We continue to view the pipeline (esp. OMS721) as a key value growth driver for OMER, though one that requires additional clinical data for validation. We maintain our Buy rating and adjust our PT to $22 (from $24)." (3/17/2017)

Who are some of Omeros Corporation's key competitors?

Who are Omeros Corporation's key executives?

Omeros Corporation's management team includes the folowing people:

  • Gregory A. Demopulos M.D., Chairman of the Board, President, Chief Executive Officer
  • Michael A. Jacobsen, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Marcia S. Kelbon J.D., Vice President - Patent, General Counsel, Secretary
  • Thomas J. Cable, Lead Independent Director
  • Peter A. Demopulos M.D., Director
  • Ray Aspiri, Independent Director
  • Arnold C. Hanish, Independent Director
  • Leroy E. Hood M.D., Ph.D., Independent Director

Who owns Omeros Corporation stock?

Omeros Corporation's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Ingalls & Snyder LLC (10.78%). Company insiders that own Omeros Corporation stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros Corporation.

Who bought Omeros Corporation stock? Who is buying Omeros Corporation stock?

Omeros Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC. View Insider Buying and Selling for Omeros Corporation.

How do I buy Omeros Corporation stock?

Shares of Omeros Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros Corporation's stock price today?

One share of Omeros Corporation stock can currently be purchased for approximately $18.95.


MarketBeat Community Rating for Omeros Corporation (NASDAQ OMER)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  371 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  537
MarketBeat's community ratings are surveys of what our community members think about Omeros Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Omeros Corporation (NASDAQ:OMER) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.40 (97.36% upside)
Consensus Price Target History for Omeros Corporation (NASDAQ:OMER)
Price Target History for Omeros Corporation (NASDAQ:OMER)
Analysts' Ratings History for Omeros Corporation (NASDAQ:OMER)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/20/2017Maxim GroupSet Price TargetBuy$24.00N/AView Rating Details
8/24/2017Cantor FitzgeraldReiterated RatingHold$15.00 -> $19.00HighView Rating Details
8/18/2017WedbushReiterated RatingOutperform$47.00LowView Rating Details
6/14/2017WBB SecuritiesReiterated RatingStrong-Buy$75.00HighView Rating Details
6/3/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/17/2017Needham & Company LLCReiterated RatingBuy -> Buy$24.00 -> $22.00HighView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Omeros Corporation (NASDAQ:OMER)
Earnings by Quarter for Omeros Corporation (NASDAQ:OMER)
Earnings History by Quarter for Omeros Corporation (NASDAQ OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.36)N/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.23)$14.63 million$17.15 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Omeros Corporation (NASDAQ:OMER)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: $0.33
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.34)($0.35)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.29)($0.21)($0.25)
Q4 20172($0.28)($0.12)($0.20)
Q1 20181($0.02)($0.02)($0.02)
Q2 20181$0.03$0.03$0.03
Q3 20181$0.14$0.14$0.14
Q4 20181$0.18$0.18$0.18
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Omeros Corporation (NASDAQ:OMER)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Omeros Corporation (NASDAQ:OMER)
Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 44.94%
Insider Trades by Quarter for Omeros Corporation (NASDAQ:OMER)
Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)
Insider Trades by Quarter for Omeros Corporation (NASDAQ:OMER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017Michael A JacobsenVPSell12,000$24.95$299,400.00View SEC Filing  
6/15/2017Michael A JacobsenVPSell24,000$21.20$508,800.00View SEC Filing  
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.00View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.84View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.00View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.40View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.60View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Omeros Corporation (NASDAQ:OMER)
Latest Headlines for Omeros Corporation (NASDAQ:OMER)
Source:
Loading headlines, please wait.

Social

Chart

Omeros Corporation (OMER) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.